Novuson Surgical Overview
Latest Deal Amount
$2.38M
Novuson Surgical General Information
Description
Provider of direct therapeutic ultrasound (DTU) technology platform created for coagulation and hemostatic control in surgical and trauma procedures. The company offers devices that use focused ultrasound energy for fast and robust hemostasis, cauterization and ablation, enabling clinicians to perform surgeries more quickly and to rapidly control bleeding associated with traumatic injuries.
Novuson Surgical Timeline
Want to dig into this profile?
We’ll help you find what you need
Learn more
Novuson Surgical Valuation & Funding
| Deal Type |
Date |
Amount |
Raised to Date |
Post-Val |
Status |
Stage |
| 5. Angel (individual) |
26-Mar-2020 |
$2.38M |
00.000 |
00.000 |
Completed |
Product Development |
| 4. Early Stage VC |
22-Jan-2019 |
|
00.000 |
|
Completed |
Product Development |
| 3. Early Stage VC |
15-Jan-2019 |
00000 |
00.000 |
|
Completed |
Product Development |
| 2. Angel (individual) |
01-Dec-2016 |
$2.63M |
$2.63M |
00.000 |
Completed |
Startup |
| 1. Grant |
01-Jan-2016 |
$2.97M |
|
|
Completed |
Startup |
Novuson Surgical Executive Team (6)
| Name |
Title |
Board Seat |
Contact Info |
| Stuart Mitchell Ph.D |
Co-Founder, Chief Science Officer, Chief Executive Officer & Board Member |
|
|
| Jean Maixner |
Executive Vice President of Operations and Finance |
|
|
| Juan Asensio MD |
Medical Advisor |
|
|
3 Former Executives